Cutera, Inc. (NASDAQ:CUTR) Shares Acquired by Bank of Montreal Can

Bank of Montreal Can lifted its position in shares of Cutera, Inc. (NASDAQ:CUTR) by 14.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 282,704 shares of the medical device company’s stock after purchasing an additional 35,248 shares during the quarter. Bank of Montreal Can owned about 1.41% of Cutera worth $455,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Bayesian Capital Management LP acquired a new position in Cutera during the first quarter valued at approximately $33,000. Ground Swell Capital LLC acquired a new position in shares of Cutera during the 2nd quarter valued at $37,000. BNP Paribas Financial Markets boosted its position in Cutera by 7.1% during the 1st quarter. BNP Paribas Financial Markets now owns 75,833 shares of the medical device company’s stock worth $111,000 after purchasing an additional 5,017 shares during the period. Finally, Opti Capital Management LP acquired a new stake in Cutera in the 4th quarter valued at $1,755,000,000. Institutional investors and hedge funds own 90.70% of the company’s stock.

Cutera Price Performance

Cutera stock opened at $0.74 on Thursday. Cutera, Inc. has a 12-month low of $0.65 and a 12-month high of $4.97. The company has a market capitalization of $14.87 million, a price-to-earnings ratio of -0.10 and a beta of 1.32. The firm’s fifty day moving average price is $0.80 and its 200 day moving average price is $1.48.

Cutera (NASDAQ:CUTR) last announced its earnings results on Thursday, August 8th. The medical device company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.55) by $0.32. The business had revenue of $34.38 million for the quarter, compared to analyst estimates of $39.47 million. Analysts forecast that Cutera, Inc. will post -5.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CUTR. Stephens reduced their price objective on Cutera from $10.00 to $5.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and set a $1.00 target price (down from $3.00) on shares of Cutera in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Cutera currently has a consensus rating of “Hold” and an average target price of $5.33.

Cutera Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.